查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1701378

感染疾病藥物市場規模、佔有率、趨勢分析報告：按感染疾病、藥物類別、分銷管道、地區、細分市場預測，2025-2030 年

Infectious Disease Therapeutics Market Size, Share & Trends Analysis Report By Infection (Bacterial, Viral), By Drug Class (Antibacterial, Antiviral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

感染疾病治療市場的成長與趨勢：

根據Grand View Research, Inc.的最新報告，全球感染疾病治療市場預計到2030年將達到2,839.1億美元，2025年至2030年的複合年成長率為3.5%。

市場成長的主要動力來自於全球人類免疫力缺乏病毒 (HIV)、人類乳突病毒 (HPV)、結核病和肝炎病例的不斷增加。

政府機構和私人公司正在大力投資醫療保健領域，用於預防、診斷和治療感染疾病。預計在預測期內，對治療感染疾病的新藥開發的投資增加以及提高人們對這些疾病的意識提升的舉措的增加將推動市場的發展。此外，隨著專利到期以及學名藥進入市場，預計感染疾病藥物的需求將因價格較低而增加。

此外，這些感染疾病的診斷和治療可以獲得報銷，加上製造商在這些疾病高發生率地區免費分發藥品，預計將進一步推動市場成長。然而，感染疾病物的低採用率和假藥數量預計將在預測期內成長抑制因素。

2016年，北美市場佔最大佔有率。大量製造商的存在、有利的報銷情況以及不斷增加的醫療保健成本是該地區佔最大佔有率的關鍵因素。然而，亞太地區很可能在 2017 年至 2025 年期間呈現最高成長率。感染疾病高發病率、亞洲國家經濟狀況改善、政府擴大採取感染疾病治療措施以及資金籌措活動的活性化是該地區在預測期內實現最高成長率的一些因素。

感染疾病藥物市場報告重點

  • 2024年，病毒感染疾病將佔據市場主導地位，佔有率為42.58%。寄生蟲感染疾病領域是成長最快的市場，其驅動力包括盛行率的上升、抗藥性的增強以及針對瘧疾、利什曼原蟲症和血吸蟲病的全球衛生舉措。
  • 到 2024 年，疫苗將佔據抗感染藥感染疾病市場的主導地位，佔有 32.75% 的佔有率。這是由於疾病盛行率上升、人們意識增強以及政府強力的疫苗接種計劃所致。由於瘧疾、利什曼原蟲症和其他寄生蟲感染疾病的盛行率不斷上升，抗寄生蟲藥物行業正在經歷強勁成長。
  • 受全球住院人數不斷增加的推動，預計到 2024 年，醫院藥局將佔據市場主導地位，收入佔有率將達到 52.19%。由於網路藥局的日益普及，其他藥局領域正在經歷快速成長，這增加了感染疾病藥物的可及性和便利性。
  • 2024年感染疾病治療藥物市場中，北美佔據主導地位，全球佔有率為38.09%。由於細菌和病毒感染疾病的日益流行以及醫療保健基礎設施的改善，亞太地區的感染疾病治療市場正在擴大。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章感染疾病藥物市場變數、趨勢與範圍

  • 市場展望
  • 市場動態
    • 市場成長要素分析
    • 市場限制因素分析
  • 感染疾病物抗藥性的出現及其相關副作用
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析

第4章感染疾病藥物市場：感染疾病業務分析

  • 2024年及2030年感染疾病市場佔有率
  • 感染疾病細分儀表板
  • 市場規模、預測與趨勢分析（依感染疾病，2018-2030 年）
  • 細菌感染疾病
  • 病毒感染
  • 黴菌感染疾病
  • 寄生蟲感染疾病

第5章感染疾病藥物市場：依藥物類別的業務分析

  • 2024 年及 2030 年藥品類別市場佔有率
  • 藥品類別細分儀表板
  • 2018-2030 年藥品類別市場規模、預測及趨勢分析
  • 抗菌劑
  • 抗病毒藥物
  • 抗真菌藥物
  • 抗寄生蟲藥物
  • 疫苗
  • 其他

第6章感染疾病藥物市場：通路業務分析

  • 2024年及2030年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 按分銷管道分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 醫院藥房
  • 零售藥局
  • 其他

第7章感染疾病藥物市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018年至2030年市場規模與預測趨勢分析：
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭格局

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Pfizer Inc.
    • AbbVie.
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb
    • Merck &Co., Inc.
    • Sandoz International GmbH
    • B. Braun SE
    • Xellia Pharmaceuticals
    • Mankind Pharma
    • Bayer AG
    • AstraZeneca
    • Boehringer Ingelheim International GmbH.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-1-68038-580-9

Infectious Disease Therapeutics Market Growth & Trends:

The global infectious disease therapeutics market size is expected to reach USD 283.91 billion by 2030, registering a CAGR of 3.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Infectious Disease Therapeutics Market Report Highlights:

  • Viral infections dominated the market with a 42.58% share in 2024. The parasitic infections segment is the fastest-growing market, driven by increasing prevalence, rising drug resistance, and global health initiatives targeting malaria, leishmaniasis, and schistosomiasis.
  • Vaccines dominated the anti-infective agents market with a 32.75% share in 2024, driven by rising disease prevalence, growing awareness, and strong government immunization programs. The antiparasitic drugs segment is experiencing significant growth due to the rising prevalence of malaria, leishmaniasis, and other parasitic infections.
  • Hospital pharmacies dominated the market with a revenue share of 52.19% in 2024, driven by the rising number of hospitalizations globally.The other pharmacy segment is experiencing rapid growth due to the increasing adoption of online pharmacies, which enhance accessibility and convenience for infectious disease therapeutics.
  • North America holds a leading position in the 2024 infectious disease therapeutics market, accounting for 38.09% of the global share. The infectious disease therapeutics market in Asia Pacific is expanding due to the rising prevalence of bacterial and viral infections and improving healthcare infrastructure.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Infection
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Infectious Disease Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing incidence of infectious diseases
      • 3.2.1.2. Increasing incidence of infectious diseases
      • 3.2.1.3. Rising initiatives for the awareness of infectious diseases
    • 3.2.2. Market Restraint Analysis
  • 3.3. 3.3.1 Emergence of resistance to infectious disease therapeutic drugs and adverse effects associated with them
  • 3.4. Business Environment Analysis
    • 3.4.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.4.1.1. Supplier Power
      • 3.4.1.2. Buyer Power
      • 3.4.1.3. Substitution Threat
      • 3.4.1.4. Threat of New Entrants
      • 3.4.1.5. Competitive Rivalry
    • 3.4.2. PESTLE Analysis
    • 3.4.3. Pipeline Analysis

Chapter 4. Infectious Disease Therapeutics Market: Infections Business Analysis

  • 4.1. Infections Market Share, 2024 & 2030
  • 4.2. Infections Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Infections, 2018 to 2030 (USD Million)
  • 4.4. Bacterial Infections
    • 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Viral Infections
    • 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.2. Human Immunodeficiency Virus (HIV/AIDS)
      • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.3. Hepatitis (Hepatitis B, Hepatitis C)
      • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.4. Influenza
      • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Fungal Infections
    • 4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Parasitic Infections
    • 4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Infectious Disease Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Antibacterials
    • 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Antivirals
    • 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Antifungals
    • 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Antiparasitic Drugs
    • 5.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.8. Vaccines
    • 5.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Infectious Disease Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospitals Pharmacies
    • 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Infectious Disease Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Infectious Disease Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Infectious Disease Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Pfizer Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Infection Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. AbbVie.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Infection Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Gilead Sciences, Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Infection Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bristol-Myers Squibb
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Infection Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merck & Co., Inc.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Infection Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sandoz International GmbH
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Infection Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. B. Braun SE
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Infection Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Xellia Pharmaceuticals
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Infection Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Mankind Pharma
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Infection Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bayer AG
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Infection Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. AstraZeneca
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Infection Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Boehringer Ingelheim International GmbH.
      • 8.5.12.1. Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Infection Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Novartis AG
      • 8.5.13.1. Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Infection Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. F. Hoffmann-La Roche Ltd
      • 8.5.14.1. Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Infection Benchmarking
      • 8.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 List of Parameters
  • Table 4 List of Distributors
  • Table 5 Global Infectious Disease Therapeutics Market, By Region, 2018 - 2030 (USD Million)
  • Table 6 Global Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 7 Global Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 8 Global Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 9 North America Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 10 North America Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 11 North America Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 12 North America Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 13 U.S. Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 14 U.S. Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 15 U.S. Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 17 Canada Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Canada Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Mexico Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 20 Mexico Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 21 Mexico Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 22 Europe Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 23 Europe Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 24 Europe Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 25 Europe Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Germany Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 27 Germany Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 28 Germany Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 29 UK Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 30 UK Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 31 UK Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 32 France Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 33 France Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 34 France Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 35 Italy Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 36 Italy Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Italy Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 38 Spain Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 39 Spain Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 40 Spain Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Denmark Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 42 Denmark Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 43 Denmark Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Sweden Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 45 Sweden Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 46 Sweden Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Norway Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 48 Norway Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Norway Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Japan Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 55 Japan Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 56 Japan Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 57 China Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 58 China Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 59 China Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 60 India Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 61 India Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 62 India Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 63 South Korea Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 64 South Korea Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 65 South Korea Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Australia Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 67 Australia Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 68 Australia Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Thailand Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 70 Thailand Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 71 Thailand Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Latin America Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 73 Latin America Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 74 Latin America Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 75 Latin America Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 76 Brazil Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 77 Brazil Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 78 Brazil Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 79 Argentina Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 80 Argentina Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 81 Argentina Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Infectious Disease Therapeutics Market, By Country, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 85 Middle East & Africa Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 89 South Africa Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 90 South Africa Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 91 South Africa Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 92 UAE Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 93 UAE Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 94 UAE Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Infectious Disease Therapeutics Market, By Infection, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Infectious Disease Therapeutics Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 97 Kuwait Infectious Disease Therapeutics Market, By Distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Astaxanthin market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Source and product segment snapshot
  • Fig. 10 Application segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market value, 2024 (USD Billion)
  • Fig. 13 Market trends & outlook
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTEL analysis
  • Fig. 16 Infectious Disease Therapeutics Market Outlook Key Takeaways
  • Fig. 17 Infectious Disease Therapeutics Market: Infection Movement Analysis
  • Fig. 18 Global Infectious Disease Therapeutics Market, by Infection, 2018 - 2030 (USD Million)
  • Fig. 19 Bacterial Infections Market, 2018 - 2030 (USD Million)
  • Fig. 20 Viral Infections Market, 2018 - 2030 (USD Million)
  • Fig. 21 Human Immunodeficiency Virus (HIV/AIDS) Market, 2018 - 2030 (USD Million)
  • Fig. 22 Hepatitis (Hepatitis B, Hepatitis C) Market, 2018 - 2030 (USD Million)
  • Fig. 23 Influenza Market, 2018 - 2030 (USD Million)
  • Fig. 24 Other Viral Infections Market, 2018 - 2030 (USD Million)
  • Fig. 25 Fungal Infections Market, 2018 - 2030 (USD Million)
  • Fig. 26 Parasitic Infections Market, 2018 - 2030 (USD Million)
  • Fig. 27 Global Infectious Disease Therapeutics Market: Drug Class Movement Analysis
  • Fig. 28 Global Infectious Disease Therapeutics Market, by Drug Class, 2018 - 2030 (USD Million)
  • Fig. 29 Antibacterials Market, 2018 - 2030 (USD Million)
  • Fig. 30 Antivirals Market, 2018 - 2030 (USD Million)
  • Fig. 31 Antifungals Market, 2018 - 2030 (USD Million)
  • Fig. 32 Antiparasitic Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 34 Others Market, 2018 - 2030 (USD Million)
  • Fig. 35 Global Infectious Disease Therapeutics Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Fig. 36 Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 37 Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • Fig. 38 Others Market, 2018 - 2030 (USD Million)
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Mexico infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Europe infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 UK infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Germany infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 France infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Italy infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Spain infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Norway infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Asia Pacific infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Japan infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 China infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 India infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Australia infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Thailand infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Latin America infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Brazil infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Argentina infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 MEA infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 South Africa infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Saudi Arabia infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 UAE infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Kuwait infectious disease therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 List of key emerging company's/disruptors/innovators